Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

INTRODUCTION: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, is approved for treatment of moderate-to-severe plaque psoriasis. Our objective was to evaluate the long-term efficacy and safety of ixekizumab in moderate-to-severe plaque psoriasis through 5 yea...

Descripción completa

Detalles Bibliográficos
Autores principales: Leonardi, Craig, Reich, Kristian, Foley, Peter, Torii, Hideshi, Gerdes, Sascha, Guenther, Lyn, Gooderham, Melinda, Ferris, Laura K., Griffiths, Christopher E. M., ElMaraghy, Hany, Crane, Heidi, Patel, Himanshu, Burge, Russel, Gallo, Gaia, Shrom, David, Leung, Ann, Lin, Chen-Yen, Papp, Kim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211779/
https://www.ncbi.nlm.nih.gov/pubmed/32200512
http://dx.doi.org/10.1007/s13555-020-00367-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211779/
https://www.ncbi.nlm.nih.gov/pubmed/32200512
http://dx.doi.org/10.1007/s13555-020-00367-x

Ejemplares similares